Mylan and Biocon to present phase-III trastuzumab biosimilar data at ASCO annual meeting
HERITAGE study shows comparable efficacy, safety and immunogenicity to branded trastuzumab in HER2-positive metastatic breast…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.